argenx in short

argenx combines the diversity of the llama immune system with antibody engineering advancing a clinical pipeline to treat patients with cancer and severe autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect.

Human antibodies for novel targets and underserved diseases

argenx develops novel human antibody medicines to unlock novel & complex targets addressing diseases that are underserved by current therapies. We combine our unique antibody discovery platform, SIMPLE Antibody™ with Fc engineering technologies to create highly differentiated antibodies with distinctive therapeutic qualities. 

Product pipeline

argenx creates antibodies with first- and best-in-class therapeutic potential. We have a diversified pipeline with two potential oncology drugs in the clinic, two autoimmune assets in the clinic and several product leads in preclinical development.  


Read more

Partnering opportunities

Collaboration agreements with pharmaceutical companies enable argenx to provide our expertise to our partners and develop therapeutic antibody candidates in multiple disease areas. We are also accessing truly novel targets through partnerships with academic research groups under our Innovative Access Program. 


Read more